IDStewardship

  • Home
  • Articles
  • LEARN ANTIBIOTICS
  • Study Guide
  • Resources
  • Q&A
  • #ASPchat
  • Contributors
  • About

Top New ID/Stewardship Journal Articles Link-O-Rama: October 2019

In this article top new literature in the field of  infectious diseases and antimicrobial stewardship is identified. This monthly rundown can help you keep up with the latest and greatest material!



Written By: Bassam Ghanem, Pharm.D., MS, BCPS

Edited By: Timothy P. Gauthier, Pharm.D., BCPS-AQ ID


Last updated: 7 October 2019

In this monthly column two infectious diseases pharmacists who physically reside thousands of miles apart and utilize Twitter to stay current with antimicrobial stewardship literature (@ABsteward [B.G.] & @IDstewardship [T.G.]) unite to identify some of the top new hot off the press articles recently published.

The following are some of the new publications we found most interesting or noteworthy that were released in September of 2019. We get to learn each month from all of these amazing publications and hope you enjoy this list as much as we enjoy putting it together!

Credit to Paul Sax for inspiring the link-o-rama component of our title this month.

1. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial | LANCET ID

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30403-7/fulltext

ASPECT-NP is an RCT that found high-dose ceftolozane-tazobactam is an efficacious and well tolerated treatment for Gram-negative nosocomial pneumonia in mechanically ventilated patients.

2. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa | CID

https://www.ncbi.nlm.nih.gov/pubmed/31545346

This large retrospective study found that ceftolozane/ tazobactam resulted in a higher rate of clinical cure and lower rates of acute kidney injury, compared to polymyxin/ aminoglycoside in patients with MDR/ XDR Pseudomonas aeruginosa.

3. Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study | Lancet Infect Dis

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30405-0/fulltext

This large retrospective cohort study found that in patients with Candidemia, ID consult decreased 90 day mortality by 19%.

4. Blood Culture Results Before and After Antimicrobial Administration in Patients With Severe Manifestations of Sepsis: A Diagnostic Study | Annals of Internal Medicine

https://annals.org/aim/article-abstract/2751453/blood-culture-results-before-after-antimicrobial-administration-patients-severe-manifestations

The FABLED investigators concluded that among patients with severe manifestations of sepsis, initiation of empirical antimicrobial therapy significantly reduces the sensitivity of blood cultures drawn shortly after treatment initiation.

5. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure | CID

https://www.ncbi.nlm.nih.gov/pubmed/31560051

This RCT found that oral vancomycin prophylaxis appears to protect against health care facility-onset CDI during in-patient stays in targeted patients during systemic antibiotic exposure.

6. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia | JAMA

https://jamanetwork.com/journals/jama/article-abstract/2752331

The LEAP 2 was an RCT that found among patients with community acquired bacterial pneumonia, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect to early clinical response at 96 hours after first dose.

7. Use of oral vancomycin for Clostridioides difficile Infection (CDI) and the risk of vancomycin-resistant Enterococci (VRE) | CID

https://www.ncbi.nlm.nih.gov/pubmed/31504328

This large VA cohort study found that patients treated with oral vancomycin were no more likely to develop VRE from clinical or surveillance sources at 3- or 6-months post CDI treatment than metronidazole-treated patients.



Additional New & Notable Publications

Multi-center evaluation of colistin broth disk elution and colistin agar test: a report from the Clinical and Laboratory Standards Institute | CMI

Inpatient Fluoroquinolone Stewardship Improves the Quantity and Quality of Fluoroquinolone-prescribing at Hospital Discharge: A Retrospective Analysis among 122 Veterans Health Administration Hospitals | CID

Improving antibiotic use through antimicrobial stewardship interventions upon discharge | ICHE 

2019 Update on Medical Overuse | JAMA Internal Med

Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin Preliminary Report | NEJM

Fixed dosing of liposomal amphotericin B in morbidly obese individuals | CID

Call to Action: The Role of Antiretroviral Stewardship in Inpatient Practice, a Joint Policy Paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine | CID

2019 Garrod Lecture: MDR efflux in Gram-negative bacteria how understanding resistance led to a new tool for drug discovery | JAC

Learning Experiences Within Infectious Diseases Pharmacy Residency Programs in the United States: A Cross-Sectional Survey | OFID

Invasive Fungal Carotiditis: A Rare Manifestation of Cranial Invasive Fungal Disease | OFID

Parenteral Fosfomycin: A New Ally in the Fight Against Multidrug Resistant Bacterial Pathogens | Pharmacotherapy

Optimising design of research to evaluate antibiotic stewardship interventions; consensus recommendations of a multinational working group | CMI

Impact of a Telehealth-based Antimicrobial Stewardship Program in a Community Hospital Health System | CID

Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men | JAMA

Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals | ICHE

Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics | AJHP

Panophthalmitis From Candida auris | Annals of Internal Medicine

What Is Known About Candida auris | JAMA

Evaluation of a multifaceted approach to antimicrobial stewardship education methods for medical residents | ICHE

Emergence of Polymyxin Resistance in Clinical Klebsiella pneumoniae  Through Diverse Genetic Adaptations: A Genomic, Retrospective Cohort Study | CID

Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: Retrospective analysis of 2016-2017 data from US hospitals | ICHE

Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation | JACC

Ceftazidime-avibactam versus carbapenems for the treatment of infections caused by Enterobacteriaceae: a meta-analysis of randomized controlled trials | IJAA

Recognizing and Overcoming Resistance to New Beta-Lactam/ Beta-Lactamase Inhibitor Combinations | Current Infectious Diseases Report

Antimicrobial Stewardship in a Hematological Malignancy Unit: Carbapenem Reduction and Decreased Vancomycin-resistant Enterococcus Infection | CID

Effect of Clinically Meaningful Antibiotic Concentrations on the Recovery of Escherichia coli and Klebsiella pneumoniae from Anaerobic Blood Culture Bottles with and Without Antibiotic Binding Resins | JCM

Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Non-Obese Patients with Enterobacteriaceae Bloodstream Infections | OFID

Higher MICs (>2 mg/L) Predict 30-day Mortality in patients with Lower Respiratory Tract Infections Caused by Multidrug and Extensively Drug Resistant Pseudomonas aeruginosa Treated with Ceftolozane/tazobactam | OFID

Searching for the Optimal Treatment for Metallo- and Serine-Beta-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam | AAC

Common bacterial infections and their treatment in hospitalized pediatric patients |AJHP

Machine learning for clinical decision support in infectious diseases: A narrative review of current applications | CMI

Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections | CMR


RECOMMENDED TO YOU


 

Filed Under: Infectious Diseases & Antimicrobial Stewardship

LEARN ANTIBIOTICS

Paperback Book

STEWARD PINS

Subscribe

Sign up for the monthly newsletter!

We will never spam you. We want you to like us. By clicking the Subscribe button, you accept the Terms of Service and Privacy Policy.

Categories

  • COVID-19
  • Healthcare At Large
  • Infectious Diseases & Antimicrobial Stewardship
  • Pharmacy News
  • Reality Check
  • Residency & Training
  • Facebook
  • Google+
  • Instagram
  • LinkedIn
  • Pinterest
  • Tumblr
  • Twitter
  • YouTube

Recent Posts

  • Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
  • The Learn Antibiotics Book
  • 2022 IDstewardship Year End Review
  • Antibiotics For Pediatric Respiratory Tract Infections In The Era Of Amoxicillin Shortages
  • What Does It Mean To Precept Responsibly & What Is The Precept Responsibly Podcast?

COVID-19

Musical Chairs & The ABCs of SARS-CoV-2 Monoclonal Antibodies

Musical Chairs & The ABCs of SARS-CoV-2 Monoclonal Antibodies

A Comparison Of Paxlovid Versus Molnupiravir: The First Oral COVID Antivirals

A Comparison Of Paxlovid Versus Molnupiravir: The First Oral COVID Antivirals

Five Things For Pharmacists To Know About The Omicron Variant

Five Things For Pharmacists To Know About The Omicron Variant

Molnupiravir – The New COVID Antiviral Named After Thor’s Hammer

Molnupiravir – The New COVID Antiviral Named After Thor’s Hammer

Tags

antibiotic Antibiotics antimicrobial stewardship bcps beta-lactam cancer Chemotherapy Clinical Controversies clinical pharmacist clinical pharmacy community pharmacist Critical Care emergency medicine Emoji Game fellowship figure1 Hepatitis C hospital pharmacist hospital pharmacy Infectious Disease infectious diseases Lifestyle MRSA NAPLEX Natural Disaster oncology pharmacist one-on-one penicillin allergy PGY2 Pharmacy Famous pharmacy fellowship Pharmacy Job pharmacy practice pharmacy residency pharmacy school pharmacy student Pharmacy technician PK-PD Compass Predatory Journals Rapid Diagnostic Testing social media student pharmacist study table transplant Zika

Penicillin Allergy Assessment Certificate Program

Recent

  • Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
  • The Learn Antibiotics Book
  • 2022 IDstewardship Year End Review
  • Antibiotics For Pediatric Respiratory Tract Infections In The Era Of Amoxicillin Shortages
  • What Does It Mean To Precept Responsibly & What Is The Precept Responsibly Podcast?

Search

Copyright 2016-2020 By Charlie Rose, LLC © · IDStewardship.com · Copyright · Privacy Policy · Terms · Contact